The 36-month beta value for SWTX is also noteworthy at 0.79. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SWTX is 65.79M, and at present, short sellers hold a 17.67% of that float. The average trading volume of SWTX on November 20, 2024 was 1.04M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SWTX) stock’s latest price update
The stock price of SpringWorks Therapeutics Inc (NASDAQ: SWTX) has jumped by 9.75 compared to previous close of 34.56. Despite this, the company has seen a gain of 14.59% in its stock price over the last five trading days. zacks.com reported 2024-11-14 that The mean of analysts’ price targets for SpringWorks Therapeutics (SWTX) points to a 92.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SWTX’s Market Performance
SWTX’s stock has risen by 14.59% in the past week, with a monthly rise of 24.40% and a quarterly drop of -4.02%. The volatility ratio for the week is 8.00% while the volatility levels for the last 30 days are 5.89% for SpringWorks Therapeutics Inc The simple moving average for the last 20 days is 17.12% for SWTX’s stock, with a simple moving average of -5.33% for the last 200 days.
Analysts’ Opinion of SWTX
Many brokerage firms have already submitted their reports for SWTX stocks, with Guggenheim repeating the rating for SWTX by listing it as a “Buy.” The predicted price for SWTX in the upcoming period, according to Guggenheim is $75 based on the research report published on February 05, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see SWTX reach a price target of $45. The rating they have provided for SWTX stocks is “Buy” according to the report published on December 01st, 2022.
H.C. Wainwright gave a rating of “Buy” to SWTX, setting the target price at $101 in the report published on January 19th of the previous year.
SWTX Trading at 16.38% from the 50-Day Moving Average
After a stumble in the market that brought SWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.66% of loss for the given period.
Volatility was left at 5.89%, however, over the last 30 days, the volatility rate increased by 8.00%, as shares surge +27.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.52% lower at present.
During the last 5 trading sessions, SWTX rose by +14.59%, which changed the moving average for the period of 200-days by -21.11% in comparison to the 20-day moving average, which settled at $32.39. In addition, SpringWorks Therapeutics Inc saw 3.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SWTX starting from Islam Saqib, who sale 49,000 shares at the price of $40.57 back on Sep 03 ’24. After this action, Islam Saqib now owns 1,063,368 shares of SpringWorks Therapeutics Inc, valued at $1,988,033 using the latest closing price.
Edris Badreddin, the Chief Operating Officer of SpringWorks Therapeutics Inc, sale 20,000 shares at $40.65 during a trade that took place back on Sep 03 ’24, which means that Edris Badreddin is holding 229,600 shares at $812,954 based on the most recent closing price.
Stock Fundamentals for SWTX
Current profitability levels for the company are sitting at:
- -2.18 for the present operating margin
- 0.94 for the gross margin
The net margin for SpringWorks Therapeutics Inc stands at -2.03. The total capital return value is set at -0.55. Equity return is now at value -59.33, with -51.12 for asset returns.
Based on SpringWorks Therapeutics Inc (SWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -30.22. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -69.0.
Currently, EBITDA for the company is -341.35 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 20.25. The receivables turnover for the company is 4.11for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.16.
Conclusion
In summary, SpringWorks Therapeutics Inc (SWTX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
